echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Effectiveness 94.5% annual output of 1 billion doses! The battle between the mRNA vaccines has begun

    Effectiveness 94.5% annual output of 1 billion doses! The battle between the mRNA vaccines has begun

    • Last Update: 2021-01-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Pharmaceutical Intelligence Network| Forest vaccine research and development came heavy news, following Pfizer, the United States biotechnology leader Moderna announced that the company COVID-19 vaccine mRNA-1273 Phase 3 clinical trials show that the vaccine has 94.5% of the population protection, the mainstream media in the United States have been reproduced.
    this is higher than the 90 per cent effectiveness previously announced by Pfizer.
    Moderna issued a statement announcing that mRNA-1273 was working well in the COVE study of the Population Protection Phase 3 clinical trial in more than 30,000 subjects in the U.S. NIH.
    who completed two vaccinations (two weeks apart) were currently infected with the new coronavirus SARS-CoV-2 in five people, while 90 people in the placebo group were infected (p<0.0001).
    -term analysis shows that vaccination is not a serious safety risk.
    the data, Moderna will apply to the FDA for emergency authorization (EUA) in the coming weeks.
    20 million vaccines in the U.S. by the end of 2020 and is expected to deliver 5-1 billion vaccines worldwide by 2021.
    also said it would simplify and reduce vaccine storage and transportation requirements to meet global demand for vaccines as quickly as possible.
    jumped after the news.
    closed up 9.58 per cent.
    And Pfizer, which last week released positive clinical results for the new crown vaccine, saw its share price fall in a row and fell another 3 per cent yesterday, with some in the market saying it had a crowding-out effect and that Moderna's vaccine was considered easier to preserve and more effective.
    refrigerator can be kept in a stable condition for several months without the need for transport at -70C! Although Pfizer and Moderna vaccines are mRNA vaccines, Pfizer/BioNTech candidates need to be kept at -70 degrees C and can only be kept for 7 days at a normal vaccine cold temperature of 2-8 degrees C, making vaccine transportation difficult.
    mode, Moderna announced that its vaccine would remain stable for 30 days at 2 to 8 degrees C, for up to 6 months at a freezing temperature of -20 degrees C, and at room temperature for up to 12 hours.
    and the vaccine doesn't have to be diluted and mixed at the time of vaccination, as Pfizer does, and is easier to use.
    : Pfizer launched a pilot program for a new crown vaccine in four U.S. states on Thursday, local time, in an attempt to address the challenges of extremely low-temperature storage in vaccine distribution.
    the author believes that the same mRNA vaccine, perhaps the stability of the two companies is not so big, perhaps only Pfizer adopted a more conservative way of storage and transportation, and whether the conditions can be relaxed is yet to be proved.
    mRNA vaccine mature mRNA vaccine in the development of new crown vaccine is to import antigen encoded mRNA into human or animal cells, express antigen proteins, induce the body to produce an immune response.
    external mRNA can activate pattern recognition of the subject, activate nonse specific immune response, and then stimulate T, B cell immune response, performance of stronger immunogenicity.
    no need to enter the nucleation, there is no risk of gene integration.
    addition, the mRNA vaccine technology platform is developed quickly, the cost is low, the preparation cycle is short and other advantages are also played in the space.
    mRNA vaccine technology is the latest three-generation vaccine technology, overcoming the challenges of delivery systems to highlight its technical advantages.
    mRNA technology has been improved for nearly three decades, and in recent years, trial and error have gradually matured in research and development attempts.
    , mRNA technology is one of the most important research and development paths in the development of new crown vaccines, among which cutting-edge mRNA vaccine companies include BioNTech, Moderna, CUREVAC, etc.
    , according to the World Health Organization (WHO), a total of six new crown vaccine development projects based on mRNA technology are in clinical development, accounting for about 13% of new crown vaccine development projects during the clinical period.
    the mRNA vaccine excels in terms of clinical data from BioNTech/Pfizer and Moderna mRNA new crown vaccines.
    approval of the new crown outbreak is an unprecedented opportunity to shorten the relevant technical standard-setting and approval process.
    Before the new crown outbreak, China's second-generation vaccine development still has a long way to go, and mRNA vaccine and other three-generation vaccines on the domestic leading enterprises have been standing on the same line with their international counterparts, once the mRNA vaccine as the table of the third-generation vaccine technology can be successfully applied, it marks the domestic vaccine industry in the next generation of vaccine technology to reach the international leading level.
    other vaccine introduction vaccine research and development mainly has 6 technical routes: detox vaccine, inactivated vaccine, genetically engineered recombination sub-unit vaccine, DNA vaccine, RNA vaccine, virus vector vaccine, each with its own characteristics.
    according to the World Health Organization, 48 new crown vaccine research and development projects have entered the clinical trial stage, of which 12 are in phase 3 clinical development stage.
    Domestic Consino Biology, Watson Biology, Zhifei Biology, Kantai Biology and other relevant listed companies also through cooperation, independent research and development and other ways to lay out the new crown vaccine research and development, China entered Phase III clinical new crown vaccine research and development path to inactivate and viral vector-based.
    Secretary of Health and Human Services Alex Azar today officially announced the release date for the vaccine, saying there will be enough vaccines available to all Americans by March or early April.
    most vulnerable people will be vaccinated by December and health care workers will be vaccinated by January.
    the dark end of the new vaccine has dawned, hoping that the new crown vaccine will be as expected to save everyone from the haze of the virus.
    source: corporate.com
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.